A comprehensive cost-utility model was developed to communicate the value of PRODUCT X, a novel direct-acting antiviral in HCV.



  • To develop a cost-utility model to optimize the economic argumentation for PRODUCT X for a USA MCO audience

  • Pragmatic literature to review the most recent approaches undertaken for HCV cost-utility models
  • Development of approach and vetting via OL ad-board
  • Systematic literature review to source model inputs
  • Construction of model wireframes in PPT to allow client feedback on ‘look and feel’ of final deliverable
  • Model development and QC according to proprietary checklist
  • Development of abstract and posters for submission to AASLD 2014, and manuscript

  • PRODUCT X CUA model – USA MCO perspective (.XLS)
  • Technical document according to AMCP specifications (.DOC)
  • Four abstracts / posters for presentation at AASLD (.PDF)
  • Manuscript for submission to Aliment. Pharmacol. Therapy (.PDF)

  • Our team became one of this client’s ‘preferred HE partners’ across its entire portfolio
  • In HCV, various follow-on modelling workstreams were commissioned, including a work productivity model, adaptation of the model to the EU and Asia, field team training, and the economic impact of task-shifting model

Learn more about how we can help with your with cost-utitly models.